Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
Public ClinicalTrials.gov record NCT01663987. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multi Center Study to Assess the Safety and Efficacy of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) Subjects Recovering From Hospitalization for an Acute Exacerbation (Hospital Discharge Study 1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospital Discharge 1)
Study identification
- NCT ID
- NCT01663987
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2012 (Actual)
- Primary completion
- May 1, 2014 (Actual)
- Completion
- May 1, 2014 (Actual)
- Last update posted
- Oct 17, 2018
2012 – 2014
United States locations
- U.S. sites
- 49
- U.S. states
- 20
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.477.001039 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 205.477.001050 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 205.477.001021 Boehringer Ingelheim Investigational Site | Florence | Alabama | — | — |
| 205.477.001046 Boehringer Ingelheim Investigational Site | Fountain Valley | California | — | — |
| 205.477.001052 Boehringer Ingelheim Investigational Site | Sacramento | California | — | — |
| 205.477.001059 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 205.477.001009 Boehringer Ingelheim Investigational Site | Stamford | Connecticut | — | — |
| 205.477.001040 Boehringer Ingelheim Investigational Site | Waterbury | Connecticut | — | — |
| 205.477.001051 Boehringer Ingelheim Investigational Site | Brandon | Florida | — | — |
| 205.477.001044 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 205.477.001037 Boehringer Ingelheim Investigational Site | Eustis | Florida | — | — |
| 205.477.001017 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 205.477.001063 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 205.477.001001 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 205.477.001004 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 205.477.001012 Boehringer Ingelheim Investigational Site | Duluth | Georgia | — | — |
| 205.477.001064 Boehringer Ingelheim Investigational Site | Belleville | Illinois | — | — |
| 205.477.001038 Boehringer Ingelheim Investigational Site | Muncie | Indiana | — | — |
| 205.477.001007 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 205.477.001014 Boehringer Ingelheim Investigational Site | Columbia | Maryland | — | — |
| 205.477.001018 Boehringer Ingelheim Investigational Site | Livonia | Michigan | — | — |
| 205.477.001068 Boehringer Ingelheim Investigational Site | Union | New Jersey | — | — |
| 205.477.001035 Boehringer Ingelheim Investigational Site | Cooperstown | New York | — | — |
| 205.477.001023 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 205.477.001061 Boehringer Ingelheim Investigational Site | Staten Island | New York | — | — |
| 205.477.001027 Boehringer Ingelheim Investigational Site | Burlington | North Carolina | — | — |
| 205.477.001032 Boehringer Ingelheim Investigational Site | Huntersville | North Carolina | — | — |
| 205.477.001020 Boehringer Ingelheim Investigational Site | Seneca | North Carolina | — | — |
| 205.477.001034 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.477.001053 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 205.477.001011 Boehringer Ingelheim Investigational Site | Dayton | Ohio | — | — |
| 205.477.001057 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 205.477.001006 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 205.477.001083 Boehringer Ingelheim Investigational Site | Downingtown | Pennsylvania | — | — |
| 205.477.001031 Boehringer Ingelheim Investigational Site | Monroeville | Pennsylvania | — | — |
| 205.477.001028 Boehringer Ingelheim Investigational Site | Anderson | South Carolina | — | — |
| 205.477.001019 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 205.477.001010 Boehringer Ingelheim Investigational Site | Fort Mill | South Carolina | — | — |
| 205.477.001025 Boehringer Ingelheim Investigational Site | Gaffney | South Carolina | — | — |
| 205.477.001002 Boehringer Ingelheim Investigational Site | Rock Hill | South Carolina | — | — |
| 205.477.001026 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 205.477.001015 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 205.477.001013 Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| 205.477.001022 Boehringer Ingelheim Investigational Site | Corsicana | Texas | — | — |
| 205.477.001055 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 205.477.001054 Boehringer Ingelheim Investigational Site | Katy | Texas | — | — |
| 205.477.001062 Boehringer Ingelheim Investigational Site | Tyler | Texas | — | — |
| 205.477.001030 Boehringer Ingelheim Investigational Site | Abingdon | Virginia | — | — |
| 205.477.001008 Boehringer Ingelheim Investigational Site | Roanoke | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01663987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 17, 2018 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01663987 live on ClinicalTrials.gov.